|
Accelerate Diagnostics, Inc. (AXDX) DCF -Bewertung
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Accelerate Diagnostics, Inc. (AXDX) Bundle
Sparen Sie Zeit und verbessern Sie die Präzision mit unserem (AXDX) DCF -Taschenrechner! Mit realen Daten von Accelerate Diagnostics, Inc. und anpassbaren Annahmen ermöglicht dieses Tool, wie ein erfahrener Investor prognostiziert, analysieren und value (AXDX).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.3 | 11.2 | 11.8 | 12.8 | 12.1 | 12.9 | 13.8 | 14.8 | 15.9 | 17.0 |
| Revenue Growth, % | 0 | 20.09 | 5.53 | 8.23 | -5.43 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 |
| EBITDA | -67.6 | -59.7 | -59.6 | -55.8 | -49.8 | -12.9 | -13.8 | -14.8 | -15.9 | -17.0 |
| EBITDA, % | -726.66 | -534.31 | -505.81 | -437.57 | -412.73 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.6 | 3.0 | 2.5 | 3.0 | 3.3 | 3.3 | 3.5 | 3.8 | 4.0 | 4.3 |
| Depreciation, % | 27.99 | 26.84 | 21.37 | 23.53 | 26.98 | 25.34 | 25.34 | 25.34 | 25.34 | 25.34 |
| EBIT | -70.2 | -62.7 | -62.1 | -58.8 | -53.0 | -12.9 | -13.8 | -14.8 | -15.9 | -17.0 |
| EBIT, % | -754.65 | -561.16 | -527.18 | -461.1 | -439.71 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 108.5 | 68.3 | 63.6 | 45.6 | 13.2 | 12.9 | 13.8 | 14.8 | 15.9 | 17.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 3.2 | 1.6 | 2.3 | 2.4 | 2.6 | 2.8 | 3.0 | 3.2 | 3.5 | 3.7 |
| Account Receivables, % | 34.66 | 13.88 | 19.69 | 18.95 | 21.74 | 21.78 | 21.78 | 21.78 | 21.78 | 21.78 |
| Inventories | 8.1 | 9.2 | 5.1 | 5.2 | 3.3 | 7.2 | 7.8 | 8.3 | 8.9 | 9.5 |
| Inventories, % | 86.68 | 82.54 | 43.01 | 40.73 | 27.45 | 56.08 | 56.08 | 56.08 | 56.08 | 56.08 |
| Accounts Payable | 2.4 | 1.3 | 2.0 | 4.5 | 4.8 | 3.3 | 3.6 | 3.8 | 4.1 | 4.4 |
| Accounts Payable, % | 25.29 | 11.55 | 16.83 | 35.3 | 39.77 | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 |
| Capital Expenditure | -.3 | -1.4 | -.6 | -.6 | -1.0 | -.9 | -.9 | -1.0 | -1.1 | -1.1 |
| Capital Expenditure, % | -3.55 | -12.2 | -5.12 | -4.34 | -8.58 | -6.76 | -6.76 | -6.76 | -6.76 | -6.76 |
| Tax Rate, % | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 |
| EBITAT | -70.1 | -62.7 | -62.1 | -58.7 | -53.8 | -12.9 | -13.8 | -14.8 | -15.9 | -17.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -76.7 | -61.6 | -56.2 | -54.0 | -49.6 | -16.1 | -11.7 | -12.6 | -13.5 | -14.4 |
| WACC, % | 16.45 | 16.47 | 16.47 | 16.45 | 16.47 | 16.46 | 16.46 | 16.46 | 16.46 | 16.46 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -44.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -15 | |||||||||
| Terminal Value | -102 | |||||||||
| Present Terminal Value | -47 | |||||||||
| Enterprise Value | -92 | |||||||||
| Net Debt | 27 | |||||||||
| Equity Value | -119 | |||||||||
| Diluted Shares Outstanding, MM | 12 | |||||||||
| Equity Value Per Share | -9.54 |
What You Will Get
- Accurate AXDX Financial Data: Pre-filled with Accelerate Diagnostics’ historical and projected data for detailed analysis.
- Fully Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch as Accelerate Diagnostics’ intrinsic value updates in real-time based on your modifications.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- User-Friendly Interface: Straightforward layout and clear guidance suitable for all skill levels.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for Accelerate Diagnostics, Inc. (AXDX).
- Adjustable Forecast Parameters: Modify highlighted cells for key assumptions such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to help you visualize your valuation outcomes.
- Designed for All Skill Levels: An easy-to-navigate layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Accelerate Diagnostics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Accelerate Diagnostics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Accelerate Diagnostics, Inc. (AXDX)?
- Accurate Data: Real Accelerate Diagnostics financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to align with your projections.
- Time-Saving: Pre-built calculations streamline your workflow and eliminate the need to start from scratch.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the healthcare sector.
- User-Friendly: Intuitive design and step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Healthcare Professionals: Assess the financial health of Accelerate Diagnostics, Inc. (AXDX) for informed decision-making.
- Investors: Develop comprehensive valuation models to evaluate investment opportunities in AXDX.
- Market Analysts: Analyze market trends and performance metrics related to Accelerate Diagnostics, Inc. (AXDX).
- Students and Educators: Utilize real-time data to enhance learning and teaching in financial analysis.
- Biotech Enthusiasts: Gain insights into how companies like Accelerate Diagnostics, Inc. (AXDX) are valued within the biotechnology sector.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations specific to Accelerate Diagnostics, Inc. (AXDX).
- Real-World Data: Historical and projected financials for Accelerate Diagnostics, Inc. (AXDX) preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to evaluate different scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company’s performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Accelerate Diagnostics, Inc. (AXDX).
- Dashboard with Visual Outputs: Visualizations including charts and tables for clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.